S-1: Raphael Pharmaceutical Files for Resale of 5.79 Million Common Shares

Raphael Pharmaceutical is registering for the resale of up to 5,787,027 shares of its common stock by selling security holders.

Summary

• Raphael Pharmaceutical Inc. has filed a registration statement for the resale of up to 5,787,027 shares of its common stock by selling security holders.
• These shares were issued in one or more private placements.
• The company will not receive any proceeds from the sale of these shares.
• The common stock is quoted on the OTCQB Marketplace under the symbol RAPH, with the last reported sale price on September 12, 2024, at $1.65 per share.
• The company is a pharmaceutical drug research and development company focused on cannabinoid-based therapies, particularly for rheumatoid arthritis (RA) and COVID-19 related inflammation.
• Raphael is currently in pre-clinical development, with a proof-of-concept clinical trial for Cannabigerol in RA patients underway in the United States, expected to finalize six months from the recruitment of the first participant.
• The company intends to seek regulatory approvals from the FDA, MOH, and EMA for its product candidates and plans to enter into royalty agreements with GMP-approved manufacturers and distributors.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is progressing with clinical trials and has plans for future growth, it also faces significant financial challenges, including operating losses and the need for additional funding. The dependence on third parties and the competitive industry landscape add to the uncertainty.

Positives

• The company has a proof-of-concept clinical trial underway in the United States for Cannabigerol in RA patients.
• The company plans to seek regulatory approvals from the FDA, MOH, and EMA for its product candidates.
• The company intends to enter into royalty agreements with GMP-approved manufacturers and distributors.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling security holders.

Risks

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company has not generated revenue from any product candidate and may never be profitable.
• The company expects that it will need to raise substantial additional funding before it can expect to complete the development of its RA product candidate or any other product candidate.
• The lack of an existing trading market could adversely impact the company's ability to raise working capital and adversely impact its ability to continue operations.
• The company is heavily dependent on the success of its product candidates, which are in various stages of pre-clinical development.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
• The company holds no patents on its products, and its business employs proprietary technology (know-how) and information may be difficult to protect and/or infringe on the intellectual property rights of third parties.
• The company manages its business through a small number of employees and key consultants.
• The company will need to expand its organization and it may experience difficulties in recruiting needed additional employees and consultants, which could disrupt its operations.
• The company relies on third parties to conduct its preclinical and, in the future, clinical studies and perform other tasks for it.
• The company will rely on third parties to grow and provide it with its active pharmaceutical ingredient, or API, and formulations.
• The company relies on third parties to supply and manufacture its product candidates, and it expects to continue to rely on third parties to manufacture its products, if approved.
• The company's executive officer, directors and certain stockholders who are beneficial owners of 5% or more of its outstanding Common Stock possess the majority of its voting power, and through this ownership, have the ability to control the company and its corporate actions.
• Investors may have difficulty in reselling their shares due to the substantial lack of liquidity of the company's Common Stock.
• As a former shell company, resales of shares of the company's restricted Common Stock in reliance on Rule 144 of the Securities Act are subject to the requirements of Rule 144(i).
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel.
• Conditions in Israel, including the armed conflict between Israel and Hamas, Hezbollah and other terrorist organizations from the Gaza Strip and Lebanon.

Future Outlook

The company anticipates needing additional financing in the near future to fund operations and continue research and development. They plan to seek regulatory approvals for their product candidates and enter into royalty agreements with manufacturers and distributors.

Industry Context

The company operates in the competitive pharmaceutical industry, specifically targeting cannabinoid-based therapies. The document notes increasing acceptance of medical cannabis and potential competition from both established and startup companies.

Comparison to Industry Standards

• The document mentions Nabiximols (Sativex), Dronabinol (Marinol), and Nabilone (Cesamet) as examples of approved pharmaceutical drug products that include parts of the cannabis plant.
• The document references a multicenter randomized control trial on the use of medical cannabidiol in Danish patients with RA and Ankylosing Spondylitis as previously published in an issue of BMJ Open in 2019.
• The document includes a table highlighting the estimated cost that RA patients incur on an annual basis based on a 2017 report from the Canadian Agency for Drugs and Technologies in Health listing specific drug products, strengths, dose forms, prices, recommended doses, and annual drug costs.

Related Party Transactions

• The document discloses consulting agreements with executive officers, including the Chief Executive Officer, Chief Financial Officer, and Chief Technology Officer, who are also members of the board of directors.
• The document discloses a service agreement with Yehuda Eliya, a member of the board of directors.

Stakeholder Impact

• Shareholders: The resale of shares by selling security holders may impact the stock price.
• Employees: The company's ability to recruit and retain skilled personnel is crucial for its success.
• Customers: The development of new therapies could provide new treatment options for patients with RA and COVID-19 related inflammation.
• Suppliers: The company relies on third parties for the manufacturing of its product candidates.
• Creditors: The company's ability to obtain additional funding is crucial for its ability to meet its obligations.

Next Steps

• Finalize the strategy for the trial site and ensure it will have the requisite number of COVID-19 patients needed for the company's trial.
• Continue the proof-of-concept clinical trial in the United States for Cannabigerol in RA patients.
• Seek patent protection in the United States and/or internationally for the RA product candidate and potentially for other product candidates.
• Apply for MOH approval, as well as the FDA and EMA approvals for the RA product candidate as well as the COVID-19 product candidate using the FDA's regulatory pathway for drug products.

Key Dates

Keywords

Raphael Pharmaceutical, common stock, resale, cannabinoids, rheumatoid arthritis, COVID-19, clinical trial, OTCQB, FDA, MOH, EMA, pharmaceutical